[Vaccination against M. tuberculosis - what next after BCG?]

Area of Science:

• Global Health
• Immunology
• Infectious Diseases

Context:

• Tuberculosis (TB) presents a significant global health challenge, with increasing incidence in developing and developed regions.
• Drug-resistant Mycobacterium tuberculosis strains are a growing concern, complicating disease control efforts.
• The existing Bacillus Calmette-Guérin (BCG) vaccine provides insufficient protection against tuberculosis.

Purpose:

• To review the current challenges in tuberculosis control and the urgent need for improved vaccination strategies.
• To explore novel vaccine development approaches for tuberculosis.
• To highlight the importance of broadly protective vaccines for diverse populations, including immunocompromised individuals.

Summary:

• The global rise in tuberculosis, exacerbated by drug resistance and HIV, necessitates enhanced prevention methods.
• Current research focuses on developing next-generation tuberculosis vaccines using strategies like attenuated strains, recombinant BCG, and novel antigen delivery systems.
• Promising vaccine candidates are progressing through clinical trials, aiming for broader and more potent immune responses.

Impact:

• Development of more effective tuberculosis vaccines could significantly reduce global disease burden and mortality.
• Improved vaccination strategies are crucial for controlling the spread of drug-resistant tuberculosis.
• New vaccines may offer protection to vulnerable populations, including those with compromised immune systems.